06.24.20
NattoPharma has entered into a partnership agreement with KD Nutra, a KD Pharma Group company, to promote a novel cardiovascular support ingredient that combines KD Nutra’s KD-PüR high-concentrate omega-3s with NattoPharma’s nature-identical vitamin K2, known commercially as MenaQ7 PharmaPure MK-7.
The partnership between these two companies will offer formulations combining EPA and DHA ≥ 70% Concentrates and MenaQ7 in a variet of custom formulations which also include complementary cardiovascular health ingredients such as plant sterols. KD’s formulation expertise allows for proprietary blends and delivery options.
KD-Pür extracts and purifies omega-3s in a pharmaceutical GMP certified facility with technology that does not use excessive heat or oxygen, and uses green technology in lieu of chemical solvents.
NattoPharma’s MenaQ7 provides additional cardiovascular health benefits as shown by extensive clinical research the company has funded, including the maintenance and promotion of arterial flexibility. MenaQ7 was developed for the company’s Rx division, Kaydence Pharma, and is part of several ongoing patient studies. Further, in addition to having two U.S. patents for cardiovascular health benefits, MenaQ7 is patent pending for the combination of omega-3s and vitamin K2.
“Nattopharma has been incubating a number of new concepts based on our high standard of clinical validation confirming true health benefits,” NattoPharma CEO Kjetil Ramsøy, said. “KD Nutra’s rich history of innovation nad stringent quality standards fits perfectly with NattoPharma’s principles, and the time is right to deliver an unsurpassed cardiovascular combination ingredient to the market.”
“With this exclusive partnership, KD Nutra’s K2ardio3 platform can provide unique and comprehensive lipid and blood vessel management products for an increasing health aging demand,” Scott Woodruff, CEO of KD Nutra, said.
The partnership between these two companies will offer formulations combining EPA and DHA ≥ 70% Concentrates and MenaQ7 in a variet of custom formulations which also include complementary cardiovascular health ingredients such as plant sterols. KD’s formulation expertise allows for proprietary blends and delivery options.
KD-Pür extracts and purifies omega-3s in a pharmaceutical GMP certified facility with technology that does not use excessive heat or oxygen, and uses green technology in lieu of chemical solvents.
NattoPharma’s MenaQ7 provides additional cardiovascular health benefits as shown by extensive clinical research the company has funded, including the maintenance and promotion of arterial flexibility. MenaQ7 was developed for the company’s Rx division, Kaydence Pharma, and is part of several ongoing patient studies. Further, in addition to having two U.S. patents for cardiovascular health benefits, MenaQ7 is patent pending for the combination of omega-3s and vitamin K2.
“Nattopharma has been incubating a number of new concepts based on our high standard of clinical validation confirming true health benefits,” NattoPharma CEO Kjetil Ramsøy, said. “KD Nutra’s rich history of innovation nad stringent quality standards fits perfectly with NattoPharma’s principles, and the time is right to deliver an unsurpassed cardiovascular combination ingredient to the market.”
“With this exclusive partnership, KD Nutra’s K2ardio3 platform can provide unique and comprehensive lipid and blood vessel management products for an increasing health aging demand,” Scott Woodruff, CEO of KD Nutra, said.